The Impact of the Soluble Epoxide Hydrolase Cascade on Periodontal Tissues

Overview

Journal Front Dent Med

Date 2025 Feb 7

PMID 39916899

Authors

Henrique Ballassini Abdalla

Thomas E Van Dyke

Affiliations

Soon will be listed here.

Abstract

Periodontitis is a chronic inflammatory disease with complex pathogenesis. Uncontrolled inflammation is driven by the immune system in response to accumulation of oral biofilm that leads to alveolar bone loss, bleeding, increased periodontal probing depth with loss of attachment of the connective tissues to the tooth, and ultimately, tooth loss. Soluble epoxide hydrolase (sEH) is an enzyme that converts epoxy fatty acids (EpFAs) produced by cytochrome P450 (CYP450) to an inactive diol. It has been shown that EpFAs display important features to counteract an exaggerated inflammatory process. Based upon this observation, inhibitors of sEH have been developed and are being proposed as a strategy to regulate proinflammatory lipid mediator production and the chronicity of inflammation. This mini review focuses on the impact of sEH inhibition on periodontal tissues focusing on the mechanisms involved. The interaction between Specialized Pro-Resolving Mediators and sEH inhibition emerges as a significant mechanism of action of sEH inhibitors that was not formerly appreciated and provides new insights into the role SPMs may play in prevention and treatment of periodontitis.

References

Hammock B, Wang W, Gilligan M, Panigrahy D . Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?. Am J Pathol. 2020; 190(9):1782-1788. PMC: 7340586. DOI: 10.1016/j.ajpath.2020.06.010. View

Van Dyke T, Bartold P, Reynolds E . The Nexus Between Periodontal Inflammation and Dysbiosis. Front Immunol. 2020; 11:511. PMC: 7136396. DOI: 10.3389/fimmu.2020.00511. View

Shan J, Hashimoto K . Soluble Epoxide Hydrolase as a Therapeutic Target for Neuropsychiatric Disorders. Int J Mol Sci. 2022; 23(9). PMC: 9099663. DOI: 10.3390/ijms23094951. View

Oppmann B, Lesley R, Blom B, Timans J, Xu Y, Hunte B . Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000; 13(5):715-25. DOI: 10.1016/s1074-7613(00)00070-4. View

Enayetallah A, French R, Thibodeau M, Grant D . Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem. 2004; 52(4):447-54. DOI: 10.1177/002215540405200403. View

Garlet G, Giannobile W . Macrophages: The Bridge between Inflammation Resolution and Tissue Repair?. J Dent Res. 2018; 97(10):1079-1081. PMC: 6169033. DOI: 10.1177/0022034518785857. View

Van Dyke T, Sima C . Understanding resolution of inflammation in periodontal diseases: Is chronic inflammatory periodontitis a failure to resolve?. Periodontol 2000. 2019; 82(1):205-213. DOI: 10.1111/prd.12317. View

Collison L, Workman C, Kuo T, Boyd K, Wang Y, Vignali K . The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007; 450(7169):566-9. DOI: 10.1038/nature06306. View

Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

10.

Viniegra A, Goldberg H, Cil C, Fine N, Sheikh Z, Galli M . Resolving Macrophages Counter Osteolysis by Anabolic Actions on Bone Cells. J Dent Res. 2018; 97(10):1160-1169. PMC: 6169030. DOI: 10.1177/0022034518777973. View

11.

Morisseau C, Goodrow M, Dowdy D, Zheng J, Greene J, Sanborn J . Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci U S A. 1999; 96(16):8849-54. PMC: 17696. DOI: 10.1073/pnas.96.16.8849. View

12.

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

13.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

14.

Cope A, Schulze-Koops H, Aringer M . The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol. 2007; 25(5 Suppl 46):S4-11. View

15.

Kurgan S, Kantarci A . Molecular basis for immunohistochemical and inflammatory changes during progression of gingivitis to periodontitis. Periodontol 2000. 2017; 76(1):51-67. DOI: 10.1111/prd.12146. View

16.

Gill S, Hammock B, Casida J . Mammalian metabolism and environmental degradation of the juvenoid 1-(4'-ethylphenoxy)-3,7-dimethyl-6,7-epoxy-trans-2-octene and related compounds. J Agric Food Chem. 1974; 22(3):386-95. DOI: 10.1021/jf60193a058. View

17.

Jin M, Kim S, Heo J, Lee M, Kim H, Paik S . Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. 2007; 130(6):1071-82. DOI: 10.1016/j.cell.2007.09.008. View

18.

Panigrahy D, Gilligan M, Serhan C, Kashfi K . Resolution of inflammation: An organizing principle in biology and medicine. Pharmacol Ther. 2021; 227:107879. DOI: 10.1016/j.pharmthera.2021.107879. View

19.

Napimoga M, Rocha E, Trindade-da-Silva C, Demasi A, Martinez E, Macedo C . Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res. 2018; 53(5):743-749. PMC: 6168335. DOI: 10.1111/jre.12559. View

20.

Mullin C, Hammock B . Chalcone oxides--potent selective inhibitors of cytosolic epoxide hydrolase. Arch Biochem Biophys. 1982; 216(2):423-39. DOI: 10.1016/0003-9861(82)90231-4. View